JOP20220271A1 - مركبات دايازينو بيريميدين كمثبطات لـ her2 - Google Patents
مركبات دايازينو بيريميدين كمثبطات لـ her2Info
- Publication number
- JOP20220271A1 JOP20220271A1 JOJO/P/2022/0271A JOP20220271A JOP20220271A1 JO P20220271 A1 JOP20220271 A1 JO P20220271A1 JO P20220271 A JOP20220271 A JO P20220271A JO P20220271 A1 JOP20220271 A1 JO P20220271A1
- Authority
- JO
- Jordan
- Prior art keywords
- compounds
- diazinopyrimidine
- her2 inhibitors
- her2
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20171221 | 2020-04-24 | ||
| PCT/EP2021/059015 WO2021213800A1 (en) | 2020-04-24 | 2021-04-07 | [1,3]DIAZINO[5,4-d]PYRIMIDINES AS HER2 INHIBITORS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JOP20220271A1 true JOP20220271A1 (ar) | 2021-10-28 |
Family
ID=70470818
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOJO/P/2022/0271A JOP20220271A1 (ar) | 2020-04-24 | 2021-10-28 | مركبات دايازينو بيريميدين كمثبطات لـ her2 |
Country Status (33)
| Country | Link |
|---|---|
| US (3) | US11608343B2 (https=) |
| EP (2) | EP4139309B9 (https=) |
| JP (2) | JP7260723B2 (https=) |
| KR (2) | KR20250016507A (https=) |
| CN (13) | CN118307543A (https=) |
| AR (1) | AR121779A1 (https=) |
| AU (1) | AU2021260721A1 (https=) |
| BR (1) | BR112022021514A2 (https=) |
| CA (1) | CA3173602A1 (https=) |
| CL (1) | CL2022002579A1 (https=) |
| CO (1) | CO2022015054A2 (https=) |
| CR (1) | CR20220537A (https=) |
| DK (1) | DK4139309T5 (https=) |
| DO (1) | DOP2022000189A (https=) |
| EC (1) | ECSP22072777A (https=) |
| ES (1) | ES3013860T3 (https=) |
| FI (1) | FI4139309T3 (https=) |
| HR (1) | HRP20250426T1 (https=) |
| HU (1) | HUE070805T2 (https=) |
| IL (2) | IL320477A (https=) |
| JO (1) | JOP20220271A1 (https=) |
| LT (1) | LT4139309T (https=) |
| MA (1) | MA59373B1 (https=) |
| MX (1) | MX2022013223A (https=) |
| PE (1) | PE20230827A1 (https=) |
| PH (1) | PH12022552745A1 (https=) |
| PL (1) | PL4139309T3 (https=) |
| PT (1) | PT4139309T (https=) |
| RS (1) | RS66557B1 (https=) |
| SI (1) | SI4139309T1 (https=) |
| SM (1) | SMT202500164T1 (https=) |
| UA (1) | UA130588C2 (https=) |
| WO (1) | WO2021213800A1 (https=) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020328598A1 (en) | 2019-08-15 | 2022-03-03 | Black Diamond Therapeutics, Inc. | Alkynyl quinazoline compounds |
| EP4100409B1 (en) * | 2020-02-03 | 2024-08-28 | Boehringer Ingelheim International GmbH | [1,3]diazino[5,4-d]pyrimidines as her2 inhibitors |
| US11608343B2 (en) | 2020-04-24 | 2023-03-21 | Boehringer Ingelheim International Gmbh | Substituted pyrimido[5,4-d]pyrimidines as HER2 inhibitors |
| TW202214641A (zh) | 2020-06-30 | 2022-04-16 | 美商艾瑞生藥股份有限公司 | Ｈｅｒ２突變抑制劑 |
| TW202309022A (zh) | 2021-04-13 | 2023-03-01 | 美商努法倫特公司 | 用於治療具egfr突變之癌症之胺基取代雜環 |
| WO2022266458A1 (en) * | 2021-06-17 | 2022-12-22 | Black Diamond Therapeutics, Inc. | 6-heterocycloalkyl-quinazoline derivatives and uses thereof |
| CR20230604A (es) | 2021-06-26 | 2024-02-19 | Array Biopharma Inc | Inhibidores de mutación de her2 |
| WO2023154124A1 (en) * | 2022-02-09 | 2023-08-17 | Enliven Therapeutics, Inc. | Acylated heterocyclic quinazoline derivatives as inhibitors of erbb2 |
| CN118715216A (zh) | 2022-03-28 | 2024-09-27 | 江苏恒瑞医药股份有限公司 | 含氮杂环类化合物、其制备方法及其在医药上的应用 |
| CA3267358A1 (en) * | 2022-04-05 | 2025-03-22 | Voronoi Inc. | Heteroaryl derivatives for the treatment of her2-related diseases |
| CN117384162A (zh) * | 2022-05-17 | 2024-01-12 | 浙江文达医药科技有限公司 | 选择性her2抑制剂 |
| WO2024027695A1 (zh) * | 2022-08-04 | 2024-02-08 | 微境生物医药科技(上海)有限公司 | 作为her2抑制剂的化合物 |
| US20240132521A1 (en) | 2022-08-22 | 2024-04-25 | Iambic Therapeutics, Inc. | Compounds and methods for modulating her2 |
| EP4637772A1 (en) | 2022-12-22 | 2025-10-29 | Boehringer Ingelheim International GmbH | Dosing schedule of a solid dispersion of a her2 inhibitor |
| AU2023410266A1 (en) | 2022-12-22 | 2025-06-12 | Boehringer Ingelheim International Gmbh | Solid dispersion of a her2 inhibitor |
| AU2023410324A1 (en) | 2022-12-22 | 2025-05-15 | Boehringer Ingelheim International Gmbh | Crystalline forms of a her2 inhibitor |
| WO2024200637A2 (en) | 2023-03-29 | 2024-10-03 | Boehringer Ingelheim International Gmbh | Dosing schedule of a her2 inhibitor |
| AU2024241633A1 (en) | 2023-03-30 | 2025-11-06 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| EP4720678A1 (en) | 2023-05-31 | 2026-04-08 | Boehringer Ingelheim International GmbH | Survivin as a biomarker for predicting the responsiveness of cancer treatment |
| CN116903615A (zh) * | 2023-06-21 | 2023-10-20 | 江苏丽源医药有限公司 | 一种妥卡替尼及其中间体的制备方法 |
| CN121568696A (zh) | 2023-07-28 | 2026-02-24 | 勃林格殷格翰国际有限公司 | 制备her2抑制剂的方法 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| CN121729231A (zh) * | 2023-09-06 | 2026-03-24 | 勃林格殷格翰国际有限公司 | 用HER2抑制剂和CYP3A和/或P-gp调节剂进行的癌症治疗 |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| US20250228858A1 (en) | 2023-12-20 | 2025-07-17 | Boehringer Ingelheim International Gmbh | Anti-cancer combination therapy |
| US20250205238A1 (en) | 2023-12-20 | 2025-06-26 | Boehringer Ingelheim International Gmbh | Anti-cancer combination therapy |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025210042A1 (en) * | 2024-04-03 | 2025-10-09 | Boehringer Ingelheim International Gmbh | Combination of zongertinib with a sos1 inhibitor for use in the treatment of cancer |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| US20250376476A1 (en) | 2024-06-11 | 2025-12-11 | Boehringer Ingelheim International Gmbh | Crystalline forms of a HER2 tyrosine kinase inhibitor |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| CN121270563A (zh) * | 2024-07-01 | 2026-01-06 | 北京鞍石生物科技股份有限公司 | 稠环化合物及其制备方法和应用 |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026027757A1 (en) | 2024-08-02 | 2026-02-05 | Boehringer Ingelheim International Gmbh | Treatment of cancer with metastases in the central nervous system |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026077844A1 (en) | 2024-10-07 | 2026-04-16 | Boehringer Ingelheim International Gmbh | Solid dispersions having stabilized emulsion particles |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW414798B (en) * | 1994-09-07 | 2000-12-11 | Thomae Gmbh Dr K | Pyrimido (5,4-d) pyrimidines, medicaments comprising these compounds, their use and processes for their preparation |
| DE19608588A1 (de) | 1996-03-06 | 1997-09-11 | Thomae Gmbh Dr K | Pyrimido [5,4-d]pyrimidine, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| AP2004003058A0 (en) | 2001-12-12 | 2004-06-30 | Pfizer Prod Inc | Quinazoline derivatives for the treatment of abnormal cell growth. |
| JP2007510708A (ja) | 2003-11-06 | 2007-04-26 | ファイザー・プロダクツ・インク | 癌の治療における選択的ｅｒｂＢ２阻害剤／抗ｅｒｂＢ抗体の組合せ |
| ATE446294T1 (de) | 2005-11-15 | 2009-11-15 | Array Biopharma Inc | N4-phenyl-chinazolin-4-aminderivate und verwandte verbindungen als inhibitoren der erbb-typ-i- rezeptortyrosinkinase zur behandlung hyperproliferativer krankheiten |
| US20070107957A1 (en) * | 2005-11-16 | 2007-05-17 | Lonnie Lehrer | Automobile propulsion system |
| JP6468611B2 (ja) | 2014-05-13 | 2019-02-13 | アリアド ファーマシューティカルズ， インコーポレイテッド | キナーゼ阻害のためのヘテロアリール化合物 |
| EP3778584A1 (en) | 2014-06-19 | 2021-02-17 | ARIAD Pharmaceuticals, Inc. | Production process of 2-chloro-4-heteroaryl-pyrimidine derivatives |
| EP3294712A4 (en) | 2015-05-13 | 2018-11-07 | ARIAD Pharmaceuticals, Inc. | Heteroaryl compounds for kinase inhibition |
| CN111032655B (zh) | 2017-08-31 | 2022-09-02 | 达纳-法伯癌症研究所股份有限公司 | Egfr和/或her2抑制剂和使用方法 |
| JP7333313B2 (ja) | 2017-09-01 | 2023-08-24 | シャンハイ ファーマシューティカルズ ホールディング カンパニー，リミティド | 窒素含有複素環化合物、製造方法、中間体、組成物および使用 |
| EP4100409B1 (en) | 2020-02-03 | 2024-08-28 | Boehringer Ingelheim International GmbH | [1,3]diazino[5,4-d]pyrimidines as her2 inhibitors |
| JP7626774B2 (ja) | 2020-02-03 | 2025-02-04 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ＨＥＲ２阻害薬としての［１，３］ジアジノ［５，４－ｄ］ピリミジン |
| US11608343B2 (en) | 2020-04-24 | 2023-03-21 | Boehringer Ingelheim International Gmbh | Substituted pyrimido[5,4-d]pyrimidines as HER2 inhibitors |
| WO2021231400A1 (en) * | 2020-05-12 | 2021-11-18 | Accutar Biotechnology, Inc. | Bis-aryl ethers containing n-acyl azetidine as egfr/her2 inhibitors |
-
2021
- 2021-04-06 US US17/223,132 patent/US11608343B2/en active Active
- 2021-04-07 CN CN202410475947.1A patent/CN118307543A/zh active Pending
- 2021-04-07 KR KR1020257002191A patent/KR20250016507A/ko active Pending
- 2021-04-07 CN CN202410490491.6A patent/CN118388490A/zh active Pending
- 2021-04-07 WO PCT/EP2021/059015 patent/WO2021213800A1/en not_active Ceased
- 2021-04-07 EP EP21716218.9A patent/EP4139309B9/en active Active
- 2021-04-07 CN CN202410479057.8A patent/CN118388487A/zh active Pending
- 2021-04-07 DK DK21716218.9T patent/DK4139309T5/da active
- 2021-04-07 IL IL320477A patent/IL320477A/en unknown
- 2021-04-07 CN CN202410481750.9A patent/CN118388488A/zh active Pending
- 2021-04-07 CN CN202410508211.XA patent/CN118388495A/zh active Pending
- 2021-04-07 HR HRP20250426TT patent/HRP20250426T1/hr unknown
- 2021-04-07 KR KR1020227040861A patent/KR102759974B1/ko active Active
- 2021-04-07 UA UAA202204335A patent/UA130588C2/uk unknown
- 2021-04-07 MX MX2022013223A patent/MX2022013223A/es unknown
- 2021-04-07 CN CN202410475949.0A patent/CN118307544A/zh active Pending
- 2021-04-07 PT PT217162189T patent/PT4139309T/pt unknown
- 2021-04-07 MA MA59373A patent/MA59373B1/fr unknown
- 2021-04-07 JP JP2022563041A patent/JP7260723B2/ja active Active
- 2021-04-07 CN CN202180030549.3A patent/CN115485277B/zh active Active
- 2021-04-07 CN CN202410490516.2A patent/CN118388491A/zh active Pending
- 2021-04-07 PE PE2022002443A patent/PE20230827A1/es unknown
- 2021-04-07 LT LTEPPCT/EP2021/059015T patent/LT4139309T/lt unknown
- 2021-04-07 RS RS20250199A patent/RS66557B1/sr unknown
- 2021-04-07 BR BR112022021514A patent/BR112022021514A2/pt active IP Right Grant
- 2021-04-07 CN CN202410494941.9A patent/CN118388492A/zh active Pending
- 2021-04-07 CN CN202410494942.3A patent/CN118388493A/zh active Pending
- 2021-04-07 FI FIEP21716218.9T patent/FI4139309T3/fi active
- 2021-04-07 EP EP24221865.9A patent/EP4566611A3/en active Pending
- 2021-04-07 CN CN202410479058.2A patent/CN118619956A/zh active Pending
- 2021-04-07 PL PL21716218.9T patent/PL4139309T3/pl unknown
- 2021-04-07 SM SM20250164T patent/SMT202500164T1/it unknown
- 2021-04-07 AR ARP210100910A patent/AR121779A1/es unknown
- 2021-04-07 CN CN202410508210.5A patent/CN118388494A/zh active Pending
- 2021-04-07 HU HUE21716218A patent/HUE070805T2/hu unknown
- 2021-04-07 SI SI202130269T patent/SI4139309T1/sl unknown
- 2021-04-07 CN CN202410481753.2A patent/CN118388489A/zh active Pending
- 2021-04-07 ES ES21716218T patent/ES3013860T3/es active Active
- 2021-04-07 PH PH1/2022/552745A patent/PH12022552745A1/en unknown
- 2021-04-07 IL IL297490A patent/IL297490B2/en unknown
- 2021-04-07 AU AU2021260721A patent/AU2021260721A1/en active Pending
- 2021-04-07 CA CA3173602A patent/CA3173602A1/en active Pending
- 2021-04-07 CR CR20220537A patent/CR20220537A/es unknown
- 2021-10-28 JO JOJO/P/2022/0271A patent/JOP20220271A1/ar unknown
-
2022
- 2022-09-14 DO DO2022000189A patent/DOP2022000189A/es unknown
- 2022-09-21 EC ECSENADI202272777A patent/ECSP22072777A/es unknown
- 2022-09-23 CL CL2022002579A patent/CL2022002579A1/es unknown
- 2022-10-21 CO CONC2022/0015054A patent/CO2022015054A2/es unknown
-
2023
- 2023-02-10 US US18/167,168 patent/US20230374021A1/en not_active Abandoned
- 2023-04-06 JP JP2023062141A patent/JP2023085489A/ja active Pending
-
2024
- 2024-06-25 US US18/753,429 patent/US20250122204A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JOP20220271A1 (ar) | مركبات دايازينو بيريميدين كمثبطات لـ her2 | |
| JOP20240124A1 (ar) | مركبات 2-أمينو-3-سيانو ثيوفين حلقية ومشتقاتها لعلاج السرطان | |
| JOP20220325A1 (ar) | مركبات 2-أمينو-3-سيانو ثيوفين تتألف من حلقات ومشتقات لعلاج السرطان | |
| SA523440916B1 (ar) | Prmt5 مشتقات كربوكساميد ثلاثية الحلقة كمثبطات | |
| EA202091491A1 (ru) | Новые бензиламинозамещенные пиридопиримидиноны и производные в качестве ингибиторов sos1 | |
| MX2023007192A (es) | Inhibidores de prmt5. | |
| PH12021550166A1 (en) | Nlrp3 inflammasome inhibitors | |
| JOP20220332A1 (ar) | مثبطات egfr تفارغية وطرق استخدامها | |
| PH12020551717A1 (en) | Dual atm and dna-pk inhibitors for use in anti-tumor therapy | |
| CY1123627T1 (el) | Παραγωγα διυδροϊμιδαζοπυραζινονης χρησιμα στη θεραπευτικη αντιμετωπιση του καρκινου | |
| HRP20050967A2 (en) | Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors | |
| CY1113269T1 (el) | Παραγωγα ινδαζολυλ αμιδιου για τη θεραπευτικη αγωγη διαταραχων διαμεσολαβουμενων υπο υποδοχεα γλυκοκορτικοειδων | |
| EA200970611A1 (ru) | Замещенные пиразолохиназолиновые производные, способ их получения и их применение в качестве ингибиторов киназы | |
| EA201070167A1 (ru) | Замещенные производные индазола, активные как ингибиторы киназы | |
| EA202192553A1 (ru) | Protac, расщепляющие рецептор эстрогена | |
| BR112014019478A2 (pt) | composto ou um sal farmacologicamente aceitável do mesmo, composição farmacêutica, uso de um composto ou de um sal farmacologicamente aceitável do mesmo, formulação inibidor do canal de sódio, métodos para tratamento e/ou prevenção de dor e de uma doença. | |
| EA202192905A1 (ru) | Соединения, содержащие n-метил-2-пиридон, и фармацевтически приемлемые соли | |
| PH12021553248A1 (en) | Heterocyclic monoacylglycerol lipase (magl) inhibitors | |
| MX2020010942A (es) | Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales. | |
| EA201591541A1 (ru) | Ингибиторы бета-секретазы 1 (bace 1) | |
| JOP20220281A1 (ar) | مركبات وتركيبات لتثبيط نشاط hif2 ألفا وطرق لاستخدامها | |
| EA201590066A1 (ru) | Дифторгексагидроциклопентаоксазинилы и дифторгексагидробензоксазинилы в качестве ингибиторов бета-секретазы 1 | |
| EA201492097A1 (ru) | 5-амино[1,4]тиазины в качестве ингибиторов бета-секретазы 1 | |
| EP4635494A3 (en) | AMIDO HETERO-ROMATIC COMPOUNDS | |
| MX2023003516A (es) | Inhibidores no covalentes de la cinasa dependiente de ciclina 7 (cdk7). |